These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 35534581)

  • 1. Harnessing the inherent power of chimeric antigen receptor (CAR)-expressing regulatory T cells (CAR-Tregs) to treat autoimmune-related disorders.
    Kahmini FR; Shahgaldi S
    Mol Biol Rep; 2022 May; 49(5):4069-4078. PubMed ID: 35534581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance.
    Zhang Q; Lu W; Liang CL; Chen Y; Liu H; Qiu F; Dai Z
    Front Immunol; 2018; 9():2359. PubMed ID: 30369931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Next Frontier of Regulatory T Cells: Promising Immunotherapy for Autoimmune Diseases and Organ Transplantations.
    Terry LV; Oo YH
    Front Immunol; 2020; 11():565518. PubMed ID: 33072105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory CAR-T cells in autoimmune diseases: Progress and current challenges.
    Riet T; Chmielewski M
    Front Immunol; 2022; 13():934343. PubMed ID: 36032080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR Treg: A new approach in the treatment of autoimmune diseases.
    Beheshti SA; Shamsasenjan K; Ahmadi M; Abbasi B
    Int Immunopharmacol; 2022 Jan; 102():108409. PubMed ID: 34863655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric Antigen Receptor Based Therapy as a Potential Approach in Autoimmune Diseases: How Close Are We to the Treatment?
    Sadeqi Nezhad M; Seifalian A; Bagheri N; Yaghoubi S; Karimi MH; Adbollahpour-Alitappeh M
    Front Immunol; 2020; 11():603237. PubMed ID: 33324420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of CAR-T cell technology in autoimmune diseases and human immunodeficiency virus infection treatment.
    Adabi N; Pordel S; Rezaee MA; Shobeiri FS; Shobeiri SS
    J Gene Med; 2023 May; 25(5):e3484. PubMed ID: 36781390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineered regulatory T cells expressing myelin-specific chimeric antigen receptors suppress EAE progression.
    De Paula Pohl A; Schmidt A; Zhang AH; Maldonado T; Königs C; Scott DW
    Cell Immunol; 2020 Dec; 358():104222. PubMed ID: 33053469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CARs: a new approach for the treatment of autoimmune diseases.
    Sun Y; Yuan Y; Zhang B; Zhang X
    Sci China Life Sci; 2023 Apr; 66(4):711-728. PubMed ID: 36346550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology.
    Mohseni YR; Tung SL; Dudreuilh C; Lechler RI; Fruhwirth GO; Lombardi G
    Front Immunol; 2020; 11():1608. PubMed ID: 32793236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric antigen receptor T
    Eskandari SK; Daccache A; Azzi JR
    Trends Immunol; 2024 Jan; 45(1):48-61. PubMed ID: 38123369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD19-targeted CAR regulatory T cells suppress B cell pathology without GvHD.
    Imura Y; Ando M; Kondo T; Ito M; Yoshimura A
    JCI Insight; 2020 Jul; 5(14):. PubMed ID: 32525846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology.
    Koristka S; Kegler A; Bergmann R; Arndt C; Feldmann A; Albert S; Cartellieri M; Ehninger A; Ehninger G; Middeke JM; Bornhäuser M; Schmitz M; Pietzsch J; Akgün K; Ziemssen T; Steinbach J; Bachmann MP
    J Autoimmun; 2018 Jun; 90():116-131. PubMed ID: 29503042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes.
    Tenspolde M; Zimmermann K; Weber LC; Hapke M; Lieber M; Dywicki J; Frenzel A; Hust M; Galla M; Buitrago-Molina LE; Manns MP; Jaeckel E; Hardtke-Wolenski M
    J Autoimmun; 2019 Sep; 103():102289. PubMed ID: 31176558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulating the regulators: Is introduction of an antigen-specific approach in regulatory T cells the next step to treat autoimmunity?
    Janssens I; Cools N
    Cell Immunol; 2020 Dec; 358():104236. PubMed ID: 33137651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor-engineered regulatory T lymphocytes: promise for immunotherapy of autoimmune disease.
    Yi L; Weifan Y; Huan Y
    Cytotherapy; 2019 Sep; 21(9):925-934. PubMed ID: 31105041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells.
    Dawson NAJ; Rosado-Sánchez I; Novakovsky GE; Fung VCW; Huang Q; McIver E; Sun G; Gillies J; Speck M; Orban PC; Mojibian M; Levings MK
    Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32817364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor costimulation domains modulate human regulatory T cell function.
    Boroughs AC; Larson RC; Choi BD; Bouffard AA; Riley LS; Schiferle E; Kulkarni AS; Cetrulo CL; Ting D; Blazar BR; Demehri S; Maus MV
    JCI Insight; 2019 Mar; 5(8):. PubMed ID: 30869654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human OX40L-CAR-T
    Rui X; Alvarez Calderon F; Wobma H; Gerdemann U; Albanese A; Cagnin L; McGuckin C; Michaelis KA; Naqvi K; Blazar BR; Tkachev V; Kean LS
    Sci Transl Med; 2024 Oct; 16(769):eadj9331. PubMed ID: 39413160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered antigen-specific regulatory T cells for autoimmune skin conditions.
    Mukhatayev Z; Ostapchuk YO; Fang D; Le Poole IC
    Autoimmun Rev; 2021 Mar; 20(3):102761. PubMed ID: 33476816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.